A4061079: Phase 1b dose‐finding study of pembrolizumab + axitinib in
1
st
line mRCC
Best Overall Response
•
37 (71.2%) patients had confirmed objective response
•
10 (19.2%) had stable disease
Atki
t l ESMO 2016
•
PFS data are immature with only 14 (26.9%) events
ns e a ,
